Startup Evaluation: Genesis Therapeutics
Company Name: Genesis Therapeutics
Location: United States
Investors: Andreessen Horowitz, Felicis, Ulu Ventures, Harpoon Ventures, Jazz Venture Partners, Jeffrey Rothschild, Mark Leslie, Menlo Ventures, Open Field Capital, Propagator Ventures, Radical Ventures, Rock Springs Capital, T. Rowe Price, BlackRock, Fidelity Investments, NVentures
Vertical: AI
Industry: Healthcare
Key Personnel:
- Ben Sklaroff (Founder)
- Evan Feinberg (CEO)
- Will McCarthy (COO)
Funding Round: Series B
Date of Funding Round: August 21, 2023
Funding Raised: $427M
Valuation: $280M
Genesis Therapeutics Raises $427M in Series B Funding
Genesis Therapeutics, a trailblazer in AI-driven healthcare, has successfully secured $427 million in its Series B funding round, held on August 21, 2023. The round attracted significant interest from top-tier investors, including Andreessen Horowitz, Felicis, Ulu Ventures, Harpoon Ventures, and others.
This substantial infusion of capital will empower Genesis Therapeutics to push the boundaries of AI technology within the healthcare industry. The company, founded by Ben Sklaroff and led by CEO Evan Feinberg and COO Will McCarthy, is on a mission to revolutionize drug discovery and development by harnessing the power of Artificial Intelligence.
Genesis Therapeutics focuses on utilizing AI algorithms and computational models to accelerate the drug discovery process, making it more efficient and effective. Their innovative approach holds the promise of leading to groundbreaking treatments for various diseases.
The success of this Series B funding, raising $427 million, reflects the confidence that a diverse range of investors has in the company’s vision. With this robust financial backing, Genesis Therapeutics is set to expand its research capabilities, attract top-tier talent, and continue its mission of transforming the healthcare sector.
This funding round represents a significant milestone for Genesis Therapeutics, positioning the company as a leader in the AI-driven healthcare revolution.
AI Products by Genesis Therapeutics
Genesis Therapeutics is dedicated to vertical AI applications in healthcare. They have developed advanced AI technologies, including language models, to enhance their product offerings. These tools are designed to process and analyze vast amounts of data, leading to more accurate and insightful results in drug discovery.
Current Trends
Genesis Therapeutics is at the cutting edge of AI advancements in the healthcare industry. By leveraging the latest technologies, the company is driving significant innovation and pushing the boundaries of what is possible in drug discovery and development.
Advanced Language Models
The company employs state-of-the-art language models to bolster its AI capabilities. These models enable Genesis Therapeutics to process complex data efficiently, resulting in enhanced accuracy and more meaningful insights in their research efforts.